Literature DB >> 12637982

Thiazolidinediones (PPARgamma ligands) increase IRS-1, UCP-2 and C/EBPalpha expression, but not transdifferentiation, in L6 muscle cells.

A Hammarstedt1, U Smith.   

Abstract

AIMS/HYPOTHESIS: Several effects of thiazolidinediones (TZD) have been shown in adipose tissue but very little is known about the effects in skeletal muscle. We examined the effects of TZD and PPARalpha ligands on the expression of different genes in L6 muscle cells.
METHODS: L6 muscle cells were exposed to PPARalpha and PPARgamma ligands for different times. The gene expression of the signalling molecules IRS-1, IRS-2, PKB/Akt, the transcription factor C/EBPalpha, the uncoupling protein UCP-2 and the adipocyte marker aP2 were measured with real-time PCR. To directly examine the effect of C/EBPalpha on gene expression, we also transfected L6 cells with this gene.
RESULTS: L6 muscle cells showed a low expression of PPARgamma 1, no expression of PPARgamma 2, and this was not changed by TZD. PPARgamma, but not PPARalpha, ligands rapidly increased the expression of C/EBPalpha while UCP-2 and in particular the IRS-1 gene was activated with a slow onset (12-24 h). In contrast, neither PKB/Akt nor IRS-2 expression were changed. Transfection with C/EBPalpha did not increase IRS-1 expression. There was no evidence of transdifferentiation of the muscle to an adipocyte phenotype by TZD since no aP2 expression was found. CONCLUSION/
INTERPRETATION: TZD increase IRS-1, UCP2 and C/EBPalpha expression in L6 muscle cells. Activation of C/EBPalpha by TZD could be necessary but it is not sufficient to account for the increased IRS-1 expression.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12637982     DOI: 10.1007/s00125-002-1002-7

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  12 in total

1.  Insulin receptor substrate (IRS) 1 is reduced and IRS-2 is the main docking protein for phosphatidylinositol 3-kinase in adipocytes from subjects with non-insulin-dependent diabetes mellitus.

Authors:  C M Rondinone; L M Wang; P Lonnroth; C Wesslau; J H Pierce; U Smith
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-15       Impact factor: 11.205

2.  Effects of troglitazone on cellular differentiation, insulin signaling, and glucose metabolism in cultured human skeletal muscle cells.

Authors:  C Kausch; J Krützfeldt; A Witke; A Rettig; O Bachmann; K Rett; S Matthaei; F Machicao; H U Häring; M Stumvoll
Journal:  Biochem Biophys Res Commun       Date:  2001-01-26       Impact factor: 3.575

3.  PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation.

Authors:  A Chawla; Y Barak; L Nagy; D Liao; P Tontonoz; R M Evans
Journal:  Nat Med       Date:  2001-01       Impact factor: 53.440

4.  Characterization of new oral antidiabetic agent CS-045. Studies in KK and ob/ob mice and Zucker fatty rats.

Authors:  T Fujiwara; S Yoshioka; T Yoshioka; I Ushiyama; H Horikoshi
Journal:  Diabetes       Date:  1988-11       Impact factor: 9.461

5.  Regulation of CCAAT/enhancer binding protein alpha (C/EBP alpha) gene expression by thiazolidinediones in 3T3-L1 adipocytes.

Authors:  N Hemati; R L Erickson; S E Ross; R Liu; O A MacDougald
Journal:  Biochem Biophys Res Commun       Date:  1998-03-06       Impact factor: 3.575

6.  Cross-regulation of C/EBP alpha and PPAR gamma controls the transcriptional pathway of adipogenesis and insulin sensitivity.

Authors:  Z Wu; E D Rosen; R Brun; S Hauser; G Adelmant; A E Troy; C McKeon; G J Darlington; B M Spiegelman
Journal:  Mol Cell       Date:  1999-02       Impact factor: 17.970

7.  Troglitazone induces GLUT4 translocation in L6 myotubes.

Authors:  S Yonemitsu; H Nishimura; M Shintani; R Inoue; Y Yamamoto; H Masuzaki; Y Ogawa; K Hosoda; G Inoue; T Hayashi; K Nakao
Journal:  Diabetes       Date:  2001-05       Impact factor: 9.461

8.  Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone.

Authors:  J J Nolan; B Ludvik; P Beerdsen; M Joyce; J Olefsky
Journal:  N Engl J Med       Date:  1994-11-03       Impact factor: 91.245

9.  Differential regulation of peroxisome proliferator activated receptor gamma1 (PPARgamma1) and PPARgamma2 messenger RNA expression in the early stages of adipogenesis.

Authors:  R Saladin; L Fajas; S Dana; Y D Halvorsen; J Auwerx; M Briggs
Journal:  Cell Growth Differ       Date:  1999-01

10.  Regulation of glucose transport in cultured muscle cells by novel hypoglycemic agents.

Authors:  T P Ciaraldi; K Huber-Knudsen; M Hickman; J M Olefsky
Journal:  Metabolism       Date:  1995-08       Impact factor: 8.694

View more
  8 in total

1.  Effect of porcine placenta steroid extract on myogenic satellite cell proliferation, transdifferentiation, and lipid accumulation.

Authors:  Eun Ju Lee; Majid Rasool Kamli; Abdul R Bhat; Smritee Pokharel; Dong-Mok Lee; Sang Hoon Kim; Tae Il Kim; SeongKoo Hong; Inho Choi
Journal:  In Vitro Cell Dev Biol Anim       Date:  2012-05-02       Impact factor: 2.416

2.  Protective properties afforded by pioglitazone against intrastriatal LPS in Sprague-Dawley rats.

Authors:  Randy L Hunter; Dong-Young Choi; Stuart A Ross; Guoying Bing
Journal:  Neurosci Lett       Date:  2008-01-22       Impact factor: 3.046

3.  Peroxisome Proliferator-Activated Receptor -β/δ, -γ Agonists and Resveratrol Modulate Hypoxia Induced Changes in Nuclear Receptor Activators of Muscle Oxidative Metabolism.

Authors:  Timothy R H Regnault; Lin Zhao; Jacky S S Chiu; Stephanie K Gottheil; Allison Foran; Siu-Pok Yee
Journal:  PPAR Res       Date:  2010-11-24       Impact factor: 4.964

4.  Agonism of Peroxisome Proliferator Receptor-Gamma may have Therapeutic Potential for Neuroinflammation and Parkinson's Disease.

Authors:  L Hunter Randy; Bing Guoying
Journal:  Curr Neuropharmacol       Date:  2007-03       Impact factor: 7.363

5.  Peroxisome proliferator-activated receptors γ/mitochondrial uncoupling protein 2 signaling protects against seizure-induced neuronal cell death in the hippocampus following experimental status epilepticus.

Authors:  Yao-Chung Chuang; Tsu-Kung Lin; Hsuan-Ying Huang; Wen-Neng Chang; Chia-Wei Liou; Shang-Der Chen; Alice Y W Chang; Samuel H H Chan
Journal:  J Neuroinflammation       Date:  2012-07-31       Impact factor: 8.322

6.  Fatty acid mimetic PBI-4547 restores metabolic homeostasis via GPR84 in mice with non-alcoholic fatty liver disease.

Authors:  Jean-Christophe Simard; Jean-François Thibodeau; Martin Leduc; Mikael Tremblay; Alexandre Laverdure; François Sarra-Bournet; William Gagnon; Jugurtha Ouboudinar; Liette Gervais; Alexandra Felton; Sylvie Letourneau; Lilianne Geerts; Marie-Pier Cloutier; Kathy Hince; Ramon Corpuz; Alexandra Blais; Vanessa Marques Quintela; Jean-Simon Duceppe; Shaun D Abbott; Amélie Blais; Boulos Zacharie; Pierre Laurin; Steven R Laplante; Christopher R J Kennedy; Richard L Hébert; François A Leblond; Brigitte Grouix; Lyne Gagnon
Journal:  Sci Rep       Date:  2020-07-29       Impact factor: 4.379

7.  Mechanisms of obesity-induced inflammation and insulin resistance: insights into the emerging role of nutritional strategies.

Authors:  Maeve A McArdle; Orla M Finucane; Ruth M Connaughton; Aoibheann M McMorrow; Helen M Roche
Journal:  Front Endocrinol (Lausanne)       Date:  2013-05-10       Impact factor: 5.555

Review 8.  An aPPARent Functional Consequence in Skeletal Muscle Physiology via Peroxisome Proliferator-Activated Receptors.

Authors:  Wendy Wen Ting Phua; Melissa Xin Yu Wong; Zehuan Liao; Nguan Soon Tan
Journal:  Int J Mol Sci       Date:  2018-05-10       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.